News & Updates

Increasing age, higher IOP tied to primary angle-closure disease in Asians
Increasing age, higher IOP tied to primary angle-closure disease in Asians
29 Jun 2022

The incidence of primary angle-closure disease (PACD) in a multi-ethnic Asian population is 3.50 percent over 6 years, a study has shown. Increasing age, higher intraocular pressure (IOP), and shallower anterior chamber contribute to the increased risk of incident PACT, while late posterior subcapsular cataract (PSC) is associated with a lower likelihood of developing PACD.

Increasing age, higher IOP tied to primary angle-closure disease in Asians
29 Jun 2022
Netarsudil use for glaucoma may cause punctal stenosis
Netarsudil use for glaucoma may cause punctal stenosis
28 Jun 2022

Use of topical netarsudil 0.02% for the treatment of glaucoma results in the development of reversible punctal stenosis, a recent study has found. This inflammation-mediated stenosis can cause tearing and related symptoms and may lead to treatment discontinuation with sufficient severity.

Netarsudil use for glaucoma may cause punctal stenosis
28 Jun 2022
Lutein/zeaxanthin an appropriate substitute for beta carotene in AREDS2
Lutein/zeaxanthin an appropriate substitute for beta carotene in AREDS2
21 Jun 2022

Supplementation with lutein/zeaxanthin instead of beta carotene is safe and does not contribute to an increase in lung cancer risk while having a potential beneficial effect on the risk of progression to late age-related macular degeneration (AMD), according to data from the Age-Related Eye Disease Study 2 (AREDS2) study.

Lutein/zeaxanthin an appropriate substitute for beta carotene in AREDS2
21 Jun 2022
Treatment outcomes for nAMD, DMO, RVO poorer in clinical practice than in trials
Treatment outcomes for nAMD, DMO, RVO poorer in clinical practice than in trials
13 Jun 2022

In clinical practice, patients with neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO), and retinal vein occlusion (RVO) see treatment outcomes that are inferior to those reported in pivotal phase 3 studies, according to a recent study.

Treatment outcomes for nAMD, DMO, RVO poorer in clinical practice than in trials
13 Jun 2022
High-frequency mutations seen in conjunctival melanoma
High-frequency mutations seen in conjunctival melanoma
06 Jun 2022

Patients with conjunctival melanoma exhibit a high frequency of BRAF and NRAS mutations, as well as ATRX and NF1 mutations, reports a study.

High-frequency mutations seen in conjunctival melanoma
06 Jun 2022